TL;DR
This study identifies the gene HECA as a potential player in congenital heart disease (CHD) by finding rare variants associated with the condition in a Chinese population. Functional analysis reveals that HECA deficiency in cardiomyocytes can disrupt cell cycle progression, promote proliferation and migration, and activate the PDGF-BB/PDGFRB/AKT signaling pathway, offering new insights into CHD pathogenesis.
What Problem Does This Paper Address?
Congenital heart disease (CHD) is a significant birth defect with complex causes, often involving genetic factors. While hundreds of genes have been linked to CHD, the precise molecular mechanisms are not fully understood, especially concerning the role of cell cycle regulators. This paper addresses the gap in knowledge regarding the involvement of HECA, a known cell cycle regulator, in the pathogenesis of CHD. Specifically, it investigates whether rare variants in HECA are associated with an increased risk of CHD in the Chinese population and explores the functional consequences of HECA deficiency in cardiomyocytes.
Methods
The researchers employed a multi-pronged approach:
- Whole-Exome Sequencing (WES): Used to identify candidate genes in a family with atrial septal defect (ASD).
- Targeted Exon Sequencing: Performed on a larger cohort of 689 sporadic CHD patients to screen for rare HECA variants.
- Sanger Sequencing: Utilized to validate identified variants.
- Bioinformatics Analysis: Population allele frequencies from gnomADv2 and pathogenicity prediction tools (CADD, SIFT, PolyPhen2, MutationTaster) were used to filter for rare and deleterious variants.
- Cell Culture and Manipulation:
- HEK293T and AC16 cells: Standard cell lines used for experiments.
- Plasmid Transfection: Introduced wild-type and mutant HECA constructs (pcDNA3.1-HECA WT-3xMyc and pcDNA3.1-HECA W137fs-3xMyc) into AC16 cells to assess the impact of the identified mutation.
- shRNA-mediated Gene Knockdown: Used lentiviral shRNA to specifically reduce HECA expression in AC16 cells to study the effects of HECA deficiency.
- Functional Assays:
- Western Blotting: Assessed protein expression levels of HECA, PDGFRB, AKT, and STAT3, and their phosphorylated forms.
- Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR): Measured mRNA expression levels of HECA and downstream signaling pathway genes.
- Cell Cycle Analysis: Determined the distribution of cells in different phases of the cell cycle using flow cytometry.
- Cell Proliferation Assay (CCK8): Quantified the rate of cell proliferation.
- Scratch Assay: Evaluated cell migration ability.
- RNA Sequencing: Performed to identify differentially expressed genes and affected signaling pathways upon HECA knockdown.
- Statistical Analysis: Employed Fisher's exact test for association analysis, Student's t-test and ANOVA for comparing experimental groups.
Datasets
- gnomADv2 (Genome Aggregation Database): Used as a control population dataset to assess the frequency of HECA variants in East Asian populations.
- Comparative Toxicogenomics Database (CTD): Used to predict correlations between HECA and congenital malformations.
- Newly Introduced Benchmarks: Not explicitly mentioned as a new benchmark, but the study contributes to the understanding of genetic associations with CHD in the Chinese population.
Key Insights and Ideas
- HECA as a Novel CHD Gene Candidate: The study provides the first evidence linking HECA variants to CHD, expanding the known genetic landscape of this condition.
- De Novo Mutation in a Family: The identification of a novel de novo mutation (p.W137fs) in a family with ASD highlights the potential for spontaneous genetic changes to contribute to CHD.
- Conservation of W137: The evolutionary conservation of the amino acid at position 137 in HECA suggests its critical functional importance.
- HECA Deficiency Impacts Cardiomyocyte Behavior: HECA deficiency doesn't just affect cell cycle progression but also significantly promotes cell proliferation and migration in cardiomyocytes, which is crucial for cardiac development.
- PDGF-BB/PDGFRB/AKT Pathway Activation: The study pinpoints a specific signaling pathway that is dysregulated upon HECA deficiency, suggesting a molecular mechanism for its effects on cardiomyocytes. This pathway is known to be involved in cell growth and survival.
Key Results
- Six Rare Deleterious HECA Variants Identified: The study identified one de novo mutation (p.W137fs) and five other rare deleterious heterozygous variants in the HECA gene in CHD patients.
- Significant Association with CHD Risk: Damaging HECA variants were significantly associated with CHD risk in the Chinese population (Fisher's exact test, p = 0.0027, OR = 6.695).
- HECA Deficiency Alters Cell Cycle: Knockdown of HECA in AC16 cells led to a decreased proportion of cells in G0/G1 phase and an increased proportion in G2/GM phase.
- Promoted Proliferation and Migration: HECA deficiency significantly increased AC16 cell proliferation (at 48 and 72 hours) and migration (at 36 and 48 hours).
- Upregulation of PDGFRB and Downstream Signaling: HECA knockdown led to increased PDGFRB protein expression and promoted PDGF-BB-induced activation of PDGFRB and AKT, but not STAT3.
Limitations and Future Work
- Limited Tissue Samples: The study acknowledges the inability to obtain cardiac tissue from CHD patients to directly assess HECA protein levels and mutations in situ.
- Cell Model Reliance: The functional analysis was primarily conducted in an AC16 cell model. Further studies are needed to validate these findings in more complex models or patient-derived cells.
- Specific Role and Pathogenic Mechanisms: While the study identifies a pathway, further research is warranted to elucidate the precise role and pathogenic mechanisms of HECA gene variants in CHD occurrence.
- In Vivo Validation: Future work should focus on in vivo studies to confirm the role of HECA in cardiac development and CHD pathogenesis.
- Broader Population Studies: While focused on the Chinese population, expanding studies to other ethnic groups could provide a more comprehensive understanding of HECA's role in CHD globally.
Summary updated